BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020 Hepatitis C Treatment
BioLineRx (NASDAQ: BLRX) announced today that it has successfully completed the
pre-clinical development of BL-8020, an orally available,
interferon-free treatment for the Hepatitis C virus (HCV), and plans to
commence a Phase I/II safety and efficacy study for BL-8020 in Europe
during the first quarter of 2013.
Since in-licensing BL-8020 in January 2012, BioLineRx has successfully
completed a number of pre-clinical studies with the therapy. The data
package is now ready for the regulatory submissions required to begin
the clinical phase of development. BioLineRx is currently engaged in the
regulatory submission process and expects to receive approval from the
regulatory authorities by the end of this year.